Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020
By nh|2020-12-03T18:24:25+01:00December 3rd, 2020|Press release, TG4001, TG4001|Comments Off on Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020
About the Author: nh
Related Posts
- First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy